

Eligibility criteria for prostate brachytherapy

Southern Cross will only reimburse the cost of prostate brachytherapy under a member's policy when the at least **one** of the following criteria is met for that member.

1. For implantation as a single therapy for treatment of low risk prostate cancer, defined as:
 - clinical stages - T1b, T1c, T2a; **and**
 - a total Gleason score between 2 and 6; **and**
 - prostate-specific antigen (PSA) is equal to or less than 10 ng/ml.

2. For implantation as a single therapy for treatment of intermediate risk prostate cancer, defined as either:
 - clinical stages - T2b; **and**
 - prostate-specific antigen is less than 10 ng/ml; **and**
 - Gleason score is less than 6.

Or

- clinical stages – T1c/2a; **and**
- prostate-specific antigen is less than 10 ng/ml; **and**
- Gleason score is 7; **and**
- less than 50% of the biopsies are positive.

Or

- clinical stages – T1c/2a; **and**
- prostate-specific antigen is 10 to 20 ng/ml; **and**
- Gleason score is less than 6; **and**
- less than 50% of the biopsies are positive.

Please also ensure you are familiar with all **policy exclusions**, including:

- Acute care
- Congenital conditions
- Cosmetic treatment/procedures
- Health screening
- Treatment of any condition not detrimental to health
- Unapproved healthcare services.

Refer to the relevant policy document for specific conditions and exceptions that apply to these exclusions.